Liver function disturbances in Guillain-Barré syndrome: A prospective longitudinal study in 100 patients

Neurology

Volumn 46, Issue 1, 1996, Pages 96-100

  Oomes, P G ^a   Van Der Meche F G A ^a   Kleyweg, R P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G; LIVER ENZYME;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GUILLAIN BARRE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; LIVER FUNCTION TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBARACHNOID HEMORRHAGE;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LIVER; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; POLYRADICULONEUROPATHY; PROSPECTIVE STUDIES;

EID: 0029922664     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.96     Document Type: Article

References (20)

1. Arnason BGW. Acute inflammatory demyelinating polyradiculoneuropathies. In Dyck PJ, Thomas PK, Lambert EH, Bunge R, eds. Peripheral neuropathy. Vol. 2. Philadelphia: WB Saunders, 1984:2050-2100.
2. Dowling PC, Cook SD. Role of infection in Guillain-Barré syndrome: laboratory confirmation of herpesviruses in 41 cases. Ann Neurol 1981;9(suppl):44-51.
3. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré syndrome. In Contemporary neurology series. Vol. 34. Philadelphia: FA Davis, 1991.
4. de Jager AEJ, Sluiter HJ. Clinical signs in severe Guillain-Barré syndrome: analysis of 63 patients. J Neurol Sci 1991; 104:143-150.
5. Van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
6. Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-1109.
7. Kuo G, Choo Q-L, Alter HJ, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-364.
8. Hanson M, Polesky HF. Factors affecting alanine aminotransferase in blood donors. In Proceedings international hepatitis workshop. Edinburgh: Nuclear Enterprises, 1982:93-97.
9. Kita E, Oku D, Hamuro A, Nishikawa F, et al. Hepatotoxic activity of Campylobacter jejuni. J Med Microbiol 1990;33: 171-182.
10. Kita E, Nishikawa F, Kamikaidou N, Nakano A, Katsui N, Kashiba S. Mononuclear cell response in the liver of mice infected with hepatotoxigenic Campylobacter jejuni. J Med Microbiol 1992;37:326-331.
11. Reddy KR, Thomas E. Campylobacter jejuni enterocolitis and hepatitis. Gastroenterology 1982;82:1156.
12. Pitkänen T, Pönkä A, Pettersson R, Kosunen TU. Campylobacter enteritis in 188 hospitalized patients. Arch Intern Med 1983;143:215-219.
13. Winer JB, Hughes RAC, Osmond C. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988;51:613-618.
14. van Doom PA, Brand A, Vermeulen M. Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 1987;37:1798-1802.
15. Imbach P, Perret BA, Babington R, Kaminski K, Morell A, Heininger HJ. Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang 1991;61:240-243.
16. Lee ML, Courter S, Tait D, Kingdon HS. A long-term evaluation of an intravenous immune globulin preparation (Gammagard) with regard to non-A, non-B hepatitis safety. In Zuckerman A, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988:596-599.
17. Rousell RH, Budinger MD, Pirofsky B, Schiff R. Prospective study on the hepatitis safety of intravenous immunoglobulin, pH 4.25. Vox sang 1991;60:65-68.
18. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993 - June 1994. MMWR 1994;43:505-509.
19. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-1650.
20. Gutteridge GN, Veys P, Newland AC. Safety of intravenous immunoglobulin for treatment of auto-immune thrombocytopenia. Acta Haematol 1988;79:88-90.